Related Experiment Videos
[Can pharmacotherapy in heart failure affect mortality?].
1Subkatedra kardiologie ILF, Praha-Krc.
Vnitrni Lekarstvi
|March 1, 1992
Summary
Angiotensin converting enzyme inhibitors offer the greatest advance in treating chronic cardiac failure, improving symptoms and prognosis. Other treatments like digitalis and inotropic agents show limited or controversial benefits for chronic heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Advanced chronic cardiac failure carries a very poor prognosis.
- Recent investigations highlight the potential of pharmacological treatments to improve outcomes.
Purpose:
- To review current pharmacological strategies for managing chronic cardiac failure.
- To evaluate the efficacy and indications of various drug classes in improving patient prognosis.
Summary:
- Angiotensin converting enzyme (ACE) inhibitors represent a significant advancement, mitigating symptoms and improving prognosis in chronic cardiac failure.
- Diuretics remain foundational, while the role of digitalis is being revised, often proving ineffective in preserved sinus rhythm.
- Inotropic agents show controversial effects in chronic failure, lacking data for improved prognosis.
- Antiarrhythmic drugs are logical for sudden cardiac death but lack supporting trial data, with amiodarone trials ongoing.
Impact:
- ACE inhibitors are indicated for severe chronic cardiac failure, with ongoing research into their use in milder forms and post-myocardial infarction.
- Current evidence suggests limited benefit and potential risks with certain inotropic agents and digitalis in chronic heart failure.
- Further research is needed to establish the role of antiarrhythmic drugs in reducing sudden cardiac death in heart failure patients.